16 unknown, 12 completed, 5 terminated, 3 not yet recruiting. 44 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 44 | Unknown 16, Completed 12, Terminated 5, Not yet recruiting 3, Recruiting 3, Withdrawn 3, Active not recruiting 2 |
Follow evolocumab: new trials by email Literature Review of evolocumab trials Research Report on evolocumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia | Phase 4 | Not yet recruiting | Amgen | 308 | 2027-01-31 | 2026-09-21 |
| RESCUE: PCSK9 Inhibitors for Carotid Vulnerable Plaque Remodeling Intervention 1, Intervention 3, Intervention 2 - Atherosclerosis Cerebral, Carotid Plaque | Phase 4 | Not yet recruiting | Keqiang Zhao | 120 | 2027-01-01 | 2026-09-15 |
| Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Controlled Trial Evolocumab(420 mg injections) - Acute Stroke | Phase 4 | Completed | The Affiliated Hospital of Xuzhou Medical University | 60 | 2025-12-20 | 2026-07-13 |
| CAPRA-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS Evolocumab, Serial photon-counting coronary computed tomography angiography, Standard Lipid-Lowering Therapy - Coronary, Coronary Artery Disease | Phase 4 | Recruiting | West China Hospital | 232 | 2025-11-19 | 2026-10-07 |
| Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study PCSK9 inhibitor, Standard Lipid-Lowering Therapy - Coronary Artery Disease | Phase 4 | Not yet recruiting | Hanyang University Seoul Hospital | 352 | 2025-07-01 | 2025-07-24 |
| Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe, Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe - Dyslipidemias, Statin Adverse Reaction | Phase 4 | Unknown | University of Salerno | 130 | 2024-05-01 | 2024-04-24 |
| Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer Evolocumab, Statin - ASCVD, Atherosclerotic Cardiovascular Disease | Phase 4 | Unknown | Xiang Xie | 620 | 2023-08-01 | 2023-08-04 |
| Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI Rosuvastatin 20 mg, Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA] - ST Elevation Myocardial Infarction (STEMI) | Phase 4 | Terminated | Henan Institute of Cardiovascular Epidemiology | 119 | 2023-04-03 | 2026-05-22 |
| Safety and Efficacy of Evolocumab in Ischemic Stroke Evolocumab - Ischemic Stroke, Acute | Phase 4 | Unknown | Second Affiliated Hospital of Guangxi Medical University | 200 | 2023-02-01 | 2023-01-25 |
| Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO) PCSK9 inhibitor, Statin - In-stent Restenosis, Major Adverse Cardiovascular Events | Phase 4 | Unknown | Lin Zhao | 200 | 2022-12-15 | 2023-11-13 |
| Cholesterol Lowering and Residual Risk in Diabetes, Type 1 Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets - Type 1 Diabetes | Phase 4 | Recruiting | NYU Langone Health | 125 | 2022-12-06 | 2026-10-28 |
| Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg - Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia | Phase 4 | Completed | Yonsei University | 108 | 2022-12-01 | 2025-03-13 |
| High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study Evolocumab 140 MG/ML, Intensive statin treatment - Cerebral Atherosclerosis | Phase 4 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 200 | 2022-11-09 | 2023-12-11 |
| The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients Evolocumab - STEMI, Dyslipidemias | Phase 4 | Unknown | Hamad Medical Corporation | 350 | 2022-11-01 | 2022-10-13 |
| EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction Evolocumab, Routine Lipid Management - Cardiovascular Disease, Myocardial Infarction | Phase 4 | Active not recruiting | Amgen | 6019 | 2022-10-26 | 2025-10-06 |
| The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk Evolocumab - Stable Coronary Disease | Phase 4 | Recruiting | Brigham and Women's Hospital | 50 | 2022-03-03 | 2025-11-04 |
| Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI Evolocumab 140 MG/ML, Standard of care (SOC) - STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI | Phase 4 | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 2166 | 2021-09-29 | 2026-04-13 |
| Effect of Evolocumab on Coronary Plaque Characteristics Evolocumab Injections - Coronary Artery Disease | Phase 4 | Completed | Annapoorna Kini | 137 | 2021-05-04 | 2023-11-18 |
| Reducing Intracranial atheroSclErosis With Repatha Repatha - Ischemic Stroke | Phase 4 | Terminated | University of California, Los Angeles | 10 | 2021-04-23 | 2023-03-15 |
| Evolocumab In Advanced Chronic Kidney Disease Trial Evolocumab, Placebo - Chronic Kidney Diseases, High Cholesterol | Phase 4 | Withdrawn | NYU Langone Health | 2021-03-01 | 2022-07-28 |
Showing 20 of 44. Sign in to see all of them.
Atherosclerosis (7) · Hypercholesterolemia (7) · Coronary Artery Disease (6) · Acute Coronary Syndrome (4) · Cardiovascular Diseases (4) · Diabetes Mellitus, Type 2 (4) · Hyperlipidemias (4) · ST Elevation Myocardial Infarction (4) · Carotid Stenosis (3) · Dyslipidemias (3) · Intracranial Arteriosclerosis (3) · Ischemic Stroke (3) · Hypercholesterolemia, Autosomal Dominant, 3 (2) · Hyperlipoproteinemia Type II (2) · Non-ST Elevated Myocardial Infarction (2)
Amgen (3) · NYU Langone Health (3) · Brigham and Women's Hospital (2) · Leonardo Clavijo (2) · Policlinico Casilino ASL RMB (2) · Annapoorna Kini (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda Ospedaliera Ordine Mauriziano di Torino (1) · Canadian Medical and Surgical Knowledge Translation Research Group (1) · Columbia University (1) · Copenhagen University Hospital, Rigshospitalet (1) · ECRI bv (1) · Hamad Medical Corporation (1) · Hanyang University Seoul Hospital (1) · Henan Institute of Cardiovascular Epidemiology (1)
United States (15) · China (6) · Canada (3) · Italy (3) · Brazil (2) · South Korea (2) · United Kingdom (2) · Australia (1) · Denmark (1) · Finland (1) · France (1) · Hungary (1) · India (1) · Mexico (1) · Sweden (1)
Leonardo Clavijo, MD, PhD (2) · Andrei C Sposito, MD,Phd (1) · Anil K Chandraker, MD (1) · Annapoorna Kini, MD (1) · Bo Hu, Doctor (1) · Candong Hong, Doctor (1) · David Charytan, MD (1) · David Mazer, MD (1) · Diana Lopez, MD (1) · Dominick Angiolillo, MD, PhD (1) · Frank LJ Visseren, prof (1) · Henry Ginsberg, MD (1) · Henry Seligman, MBBS (1)
PMID 21543628, PMID 221537, PMID 24161333, PMID 25773607, PMID 25825402, PMID 26039521, PMID 28304224, PMID 29653628, PMID 30403574, PMID 30779243, PMID 31248666, PMID 31504418, PMID 31800032, PMID 31887831, PMID 31917184, PMID 32370478, PMID 33062236, PMID 33356392, PMID 33893754, PMID 34453829, PMID 34604796, PMID 34651329, PMID 34695894, PMID 34750081, PMID 34887772, PMID 34964815, PMID 35143424, PMID 35508320, PMID 35736631, PMID 35760720, PMID 36017568, PMID 36031810, PMID 36602868, PMID 37416519, PMID 37565307, PMID 37775612, PMID 38583289, PMID 39764289, PMID 40875095, PMID 40907505, PMID 41309899, PMID 41560483, PMID 41847515, PMID 42666092
2018 (1)